Biopharmaceuticals - Immunotherapy & Personalized Medicine
Strategic Profile
Lead product candidates include VB10.NEO, a cancer neoantigen vaccine in phase I/IIa clinical trial, and VB10.16, a therapeutic vaccine in phase II clinical trial for HPV16-induced malignancies. The company is utilizing its APC-targeted technology to create an immune tolerance platform for potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.
Cyborg Score Rationale
Nykode demonstrates solid fundamentals with validated Vaccibody platform technology, multiple clinical-stage candidates with positive interim data, and strategic partnerships (Nektar). However, as a clinical-stage company with no approved products, it carries inherent development and market risk typical of early-stage biotech.
Top Insights
Core Vaccibody platform validated in clinical trials with proof-of-concept for both cancer vaccines and immune tolerance applications
VB10.NEO individualized neoantigen vaccine backed by proprietary NeoSELECT platform with USPTO patent protection through 2039
Strategic partnership with Nektar Therapeutics for combination studies demonstrates external validation and competitive positioning
Dual therapeutic focus on cancer immunotherapy and emerging autoimmune/allergy indication space positions company for multiple commercial pathways
Named Competitors
mRNA cancer vaccines — Personalized mRNA-based cancer immunotherapies